Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Brandes International ETF (BINV)

Brandes International ETF (BINV)
33.91 -0.07 (-0.21%) 10:20 ET [NYSE Arca]
33.89 x 29 33.98 x 1200
Realtime by (Cboe BZX)
33.89 x 29 33.98 x 1200
Realtime - - (-) -
Quote Overview for Mon, Mar 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
33.86
Day High
33.95
Open 33.95
Previous Close 33.98 33.98
Volume 3,376 3,376
Avg Vol 29,790 29,790
Stochastic %K 60.88% 60.88%
Weighted Alpha +15.53 +15.53
5-Day Change -0.62 (-1.79%) -0.62 (-1.79%)
52-Week Range 28.28 - 34.63 28.28 - 34.63
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Brandes Investments
  • Assets Under Management 171,599,000
  • Shares Outstanding, K 5,050
  • 60-Month Beta N/A
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 0.72 (2.11%)
  • Most Recent Dividend 0.158 on 12/30/24
  • Management Fee 0.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.55 +4.03%
on 03/04/25
Period Open: 32.76
34.63 -2.22%
on 03/19/25
+1.10 (+3.36%)
since 02/24/25
3-Month
29.14 +16.20%
on 01/13/25
Period Open: 30.15
34.63 -2.22%
on 03/19/25
+3.72 (+12.33%)
since 12/24/24
52-Week
28.28 +19.74%
on 04/16/24
Period Open: 29.54
34.63 -2.22%
on 03/19/25
+4.32 (+14.63%)
since 03/22/24

Most Recent Stories

More News
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Regulatory News:

BINV : 33.91 (-0.21%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.38 (+7.69%)
BINV : 33.91 (-0.21%)
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

Regulatory News:

BINV : 33.91 (-0.21%)
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

Regulatory News:

BINV : 33.91 (-0.21%)
Transgene and BioInvent Announce Positive Progress for BT-001

Regulatory News:

BINV : 33.91 (-0.21%)
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on...

EXEL : 37.20 (+0.65%)
BINV : 33.91 (-0.21%)
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade

Regulatory News:

BINV : 33.91 (-0.21%)
BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment

LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV) Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company...

BINV : 33.91 (-0.21%)
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

LUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV) - Partial response in metastatic uveal melanoma, a difficult-to-treat indication - Markedly improvement of stage IV sarcoma...

BINV : 33.91 (-0.21%)
MRK : 92.44 (-0.72%)
BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma - Complete responses lasting beyond 18, 24 and 36 months LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent...

BINV : 33.91 (-0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Brandes International ETF seeks long-term capital appreciation by investing in equity securities of non-U.S. issuers that the Fund's investment team believes are undervalued relative to their financial strength and upside potential.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 34.15
2nd Resistance Point 34.08
1st Resistance Point 34.03
Last Price 33.91
1st Support Level 33.91
2nd Support Level 33.84
3rd Support Level 33.79

See More

52-Week High 34.63
Last Price 33.91
Fibonacci 61.8% 32.20
Fibonacci 50% 31.46
Fibonacci 38.2% 30.71
52-Week Low 28.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals